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Cardiovascular Disease and Glycemic
Treatment
ZACHARY T. BLOOMGARDEN, MD
A
t the 57th Annual Advanced Post-
graduate Course of the American
Diabetes Association (ADA) held
5–7February2010inSanFrancisco,Cal-
ifornia, Peter Raven (Phoenix, AZ) ad-
dressed the question of which patients
should be targeted for glucose control as
pertains to cardiovascular disease (CVD).
He termed “the big question [for] tight
glucosecontrol. . .[whether]thebeneﬁts
of tight glycemic control, cardiovascular
but, of course, also microvascular, out-
weigh the risks of hypoglycemia, mortal-
ity,time,andqualityoflife.”TheDiabetes
Control and Complications Trial (DCCT)
(1) and the Stockholm Diabetes Interven-
tion Study (2) in persons with type 1 di-
abetes and the University Group Diabetes
Program (UGDP) (3), UK Prospective Di-
abetes Study (UKPDS) (4), Kumamoto
(5), and the Veterans Affairs Cooperative
Study(6)intype2diabeteswerefollowed
by the Action to Control Cardiovascular
Risk in Diabetes (ACCORD) (7), the Ac-
tion in Diabetes and Vascular Disease:
Preterax and Diamicron-MR Controlled
Evaluation (ADVANCE) (8), and the Vet-
erans Affairs Diabetes Trial (VADT) (9)
that addressed a glycemic goal of A1C
from7%andgoingtoevenlowerlevels.
Comparing the older with newer
studies, although we have a good under-
standing of the relationship between con-
trol and microvascular risk, Reaven
suggested that the DCCT and UKPDS ap-
pear to show that the relationship of gly-
cemia to outcome for microvascular
diseaseshowsasteeperslopethanthatfor
macrovascular disease, making it more
difﬁcult to determine the importance of
thelatter.IntheDCCTitself,therewasno
signiﬁcant cardiovascular beneﬁt, al-
though the trial was not intended for this.
This was similarly the case for Kum-
amoto; in UKPDS, the 16% decrease in
myocardial infarction was not statistically
signiﬁcant at the completion of the trial,
althoughallthreetrialsshowedreduction
inmicrovasculardisease.UKPDSalsohad
a metformin arm, which did show signif-
icant cardiovascular reduction with
monotherapy, although not when the
agent was given in combination with a
sulfonylurea (10). In these studies, how-
ever, blood pressure and lipids were not
as aggressively treated as is currently
done, which may limit our ability to ex-
trapolate to current beneﬁts.
TheDCCT/EpidemiologyofDiabetes
Interventions and Complications (EDIC)
follow-up did show cardiovascular bene-
ﬁt (11), leading to the concepts that this
may require long periods of time and that
there may be beneﬁt to early control. The
UKPDS follow-up similarly showed sig-
niﬁcant cardiovascular beneﬁt a decade
following the end of intensive treatment
(12). There is, then, possible long-term
cardiovascular beneﬁt of glycemic treat-
ment in type 1 and type 2 diabetes, but it
appears to be slow in onset, with little
data showing cardiovascular beneﬁt of
achievingA1Clevels7%.Arecentanal-
ysis of type 2 diabetic persons from the
U.K. General Practice Research Database,
27,965 whose treatment had been inten-
siﬁedfromoralmonotherapytocombina-
tion therapy and 20,005 who had
changed to regimens that included insu-
lin, suggested that either above or, more
worrisomely,belowanA1Clevelof7.5%,
mortality increased (13).
In the three more recent trials,
ACCORD, ADVANCE, and VADT, that
included persons with longer diabetes
duration and higher CVD prevalence and
that had more aggressive A1C goals, the
outcomes for cardiovascular reduction
were modest, with reductions ranging
from 6 to 12%, which were not statisti-
callysigniﬁcant.Furthermore,therewasa
signiﬁcant 22% increase in total mortal-
ity, with increased cardiovascular mortal-
ity, in the intensive treatment group of
ACCORD.Prespeciﬁedsubgroupanalysis
showed,however,thatthosewhohadnot
hadpriorcardiovasculareventsandthose
who had baseline A1C 8% seemed to
have beneﬁt in reduction of primary out-
come, with mortality also appearing to
show this pattern.
In ADVANCE, macrovascular event
rates were not different despite the 0.7%
difference in A1C. In the VADT, 1,791
patients were treated in 20 centers in a
prospective, randomized fashion, with
blood pressure, lipids, diet and lifestyle
approaches identical in the intensive ver-
sus conventional glucose control arms,
over an average follow-up of 5.6 years,
with A1C 6.4 vs. 8.4%. There was a non-
signiﬁcant 12% lower rate of the primary
composite outcome of cardiovascular
death, myocardial infarction, stroke,
heart failure, surgery for vascular disease,
inoperablecoronarydisease,andamputa-
tion for ischemic gangrene. Hypoglyce-
mia rates tripled, however, in all types
from mild to more severe, and this was a
strong predictor of cardiovascular death
for both the standard and intensive care
groups. There was a trend (P  0.07) to
decreased 2-step retinopathy progres-
sion,areductioninprogressionfromnor-
mal to micro- or macroalbuminuria, no
difference in mononeuropathy or periph-
eralneuropathy,andatrend(P0.07)to
worsening of autonomic neuropathy.
A meta-analysis of ACCORD,
ADVANCE, UKPDS, and VADT, with a
total of 27,049 participants with 2,370
major vascular events, showed a signiﬁ-
cant 9% reduction in these events, driven
by a 15% reduction in myocardial infarc-
tion, with nonsigniﬁcant 10 and 4% in-
creases in cardiovascular and total
mortality, respectively. Hypoglycemia
rates were 2.5-fold more common with
intensive treatment. There was heteroge-
neity between the trials, with ADVANCE
suggesting a reduction in cardiovascular
mortality, the UKPDS being neutral, and
ACCORD and VADT having trends to in-
creased cardiovascular mortality. In the
meta-analysis, those with no history of
macrovascular disease had a signiﬁcant
16% reduction in CVD, while there was
no cardiovascular beneﬁt in those who
hadsuchahistory—theinteractionbased
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being statistically signiﬁcant (14).
Prospective coronary artery calcium
(CAC) scans were done in 301 partici-
pants in the VADT. Those with Agatston
score 100 did not have signiﬁcant ben-
eﬁt, while those with score 100 had a
marked reduction in events with inten-
sive glycemic control, with nearly a 10-
fold difference in the beneﬁt ratio (15).
Reavenstatedthat“howyouenterthetrial
intermsofyourvascularstatusmayinﬂu-
ence how you do.” This may, he sug-
gested, explain the negative ﬁndings of
the overall study because nearly two-
thirdsoftheVADTcohortlikelyhadCAC
100. It may be, then, that those with
advanced CVD may not have cardiovas-
cular beneﬁt from intensive glycemic
treatment. Indeed, in a study of 2,613
type 2 diabetic patients, those with low-
to-moderate scores had 40% better car-
diovascular outcome with A1C 6.5%
than at higher levels, while those with
high comorbidity scores had a nonsignif-
icant 9% reduction in CVD (16). Early
disease, Reaven concluded, may be par-
ticularly beneﬁted from intensive glyce-
mictreatment,whereastheremaybelittle
beneﬁt, or beneﬁt outweighed by harm
from hypoglycemia, in persons with dia-
betes and advanced CVD. Another possi-
bility is that the time required for beneﬁt
to occur in those persons may be so long
that adverse effects of treatment predom-
inateduringtheperiodofatypicalclinical
trial. We continue to need to treat other
cardiovascular risk factors aggressively,
Reaven pointed out, but it may be appro-
priate to avoid very aggressive A1C low-
ering in older persons and in those with
diabetes of longer duration, frequent or
severehypoglycemia,extensivemicrovas-
culardisease,orwithmoreCVD(imaging
might be useful in assessing this).
Hypoglycemia
I further discussed questions of hypogly-
cemia and other adverse consequences of
glucose-lowering therapies in the three
recent trials and reviewed the conceptual
dilemma that although analysis showed
no signiﬁcant association of severe hypo-
glycemia with the increased mortality in
ACCORD, there are many reasons to
think that it may have played a role as
severe hypoglycemia was signiﬁcantly as-
sociated with higher mortality and as
there is no doubt that the very aggressive
treatment approach undertaken in the
trialledtomarkedlyincreasedratesofhy-
poglycemiaintheinterventiongroup.Itis
worthwhile to examine the deﬁnition of a
severe hypoglycemia episode used in AC-
CORD: hypoglycemia requiring medical
or paramedical attention with either doc-
umented blood glucose 50 mg/dl or
prompt recovery with administration of
oral carbohydrate, parenteral glucose, or
subcutaneous glucagon. Each partici-
pant’s “Glucose Diary” was reviewed at
each clinic visit to identify the occurrence
of one of these hypoglycemic events. Us-
ing these criteria, hypoglycemia occurred
in 10.3 vs. 3.4% of the intensive versus
control group in ACCORD (17); severe
hypoglycemia not necessarily requiring
medical attention occurred in 16.2 vs.
5.1%, with presumably related rates of
weight gain exceeding 10 kg of 27.8 vs.
14.1%, respectively (7). The rates of doc-
umented blood glucose 50 mg/dl for
the respective groups in VADT were 203
vs. 52 per 100 patient-years (9); this oc-
curred much less frequently in
ADVANCE, in 2.7 vs. 1.5% of the respec-
tive groups during the period of observa-
tion (8). Severe hypoglycemia was itself a
strong risk factor for mortality; those per-
sons with one or more episodes requiring
medical assistance had annual mortality
rates of 2.8% in the intensive control
arm—less than the rate of 4.9% in the
standard control arm—a paradoxical
ﬁnding in view of the overall increase in
mortality reported in the former group.
Indeed, among those not experiencing
any hypoglycemic events requiring assis-
tance, annual mortality rates were 1.2%
with intensive treatment and 1.0% with
standard treatment (17). Although the
ACCORD investigators concluded that
“the increased risk of death seen in the
ACCORD trial among participants in the
intensive glycaemia control arm cannot
be attributed to the increased rate of se-
vere hypoglycemia in intensive arm par-
ticipants (17),” it appears that there was
no systematic attempt to capture overall
rates of asymptomatic hypoglycemia with
analysis of downloaded glucose meter
data. One wonders whether, if such in-
formation were available, it might be
found that the increase in mortality in
theintensivecontrolgroupamongthose
not experiencing documented severe hy-
poglycemia might actually reﬂect what
couldbetermedasymptomaticseverehy-
poglycemia. This suspicion may be bol-
steredbyanalysisofthecausesofdeathin
ACCORD: 86 of 136 cardiovascular
deathsintheintensivegroupand67of94
in the standard treatment group were
sudden/unexpected,ofthesortthatmight
be brought about by a severe hypoglyce-
mic episode, so that although only one
documented death occurred with severe
hypoglycemia,glucosemeasureswerenot
available near the times of death for most
cases. Similarly, in the VADT, there were
29 cardiovascular deaths in the standard
versus 36 in the intensive glycemic treat-
ment groups, with sudden death in 4 vs.
11, accounting for all of the excess mor-
tality, and recent severe hypoglycemia
was associated with a fourfold increase in
cardiovascularmortality(18).Indeed,itis
fascinating that hyperglycemia remained
a mortality predictor in ACCORD; those
participants with baseline A1C 8.5%
had greater mortality (19), and every 1%
lowerA1Cwasassociatedwithmorethan
a 50% reduction in mortality, so that an
in-study A1C above 7% was associated
with higher mortality (20). One would be
tempted,then,toconcludethatacontrib-
utor to mortality was the state of difﬁcult-
to-control diabetes, leading the
investigators to fruitlessly increase their
efforts to lower glucose levels in patients
who for one or another reason responded
poorly to such efforts.
I reviewed corroborative evidence
from the Treating To Target in Type 2
Diabetes (4-T) study of 708 patients not
optimally controlled with sulfonylureas
plus metformin, where the less aggressive
basal insulin ﬁrst approach reduced
weight gain and severe hypoglycemia,
leading to a substantial difference in ad-
verse events, with cardiovascular death in
one, four, and nine persons randomized
to initial use of basal, biphasic, and pran-
dial bolus insulin, respectively (21). Doc-
umented severe hypoglycemia is likely to
represent a tiny fraction of overall hypo-
glycemia. In a study comparing basal in-
sulin glargine to prandial insulin lispro in
415 type 2 diabetic patients who received
oral agents, the groups had 5.21 and
24.00 total hypoglycemic episodes per
patient per year, but 0.03 and 0.08 severe
hypoglycemic episodes per patient per
year (22). It is likely then that severe but
asymptomatic hypoglycemic episodes do
occur, and there is no reason to suppose
that such episodes do not have cardiovas-
cular consequence, perhaps even more so
than those for which the patient is able to
obtain assistance. Further suggestion that
treatments likely to cause hypoglycemia
(insulin and sulfonylureas) might have
particularly adverse cardiovascular con-
sequence over approaches not intrinsi-
cally causing hypoglycemia (metformin
and rosiglitazone) comes from the Bypass
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tion in Type 2 Diabetes (BARI 2D) trial of
2,368 type 2 diabetic persons with angio-
graphically documented coronary artery
disease (23). The former treatment strat-
egy led to 38 and 56% increases in total
and in severe hypoglycemia, with a trend
to increasing major cardiovascular events
in those patients undergoing coronary ar-
tery bypass surgery. In considering very
intensive glycemic treatment we should, I
concluded, remember Elliott Joslin’s dic-
tum:“Insulinisaremedyprimarilyforthe
wise and not for the foolish, whether they
be patients or doctors” (reported in [24]).
Blood pressure and lipid treatment
David Kendall (Alexandria, VA), Chief
Scientiﬁc and Medical Ofﬁcer of ADA,
discussed the treatment of other cardio-
vascular risk factors in diabetes. “It is
quiteclear,”hesaid,“thatdiabetes,inpar-
ticulartype2diabetes,isassociatedwitha
myriad of risk factors . . . that contribute
to the increased cardiovascular risk.”
Much of the discussion of A1C targets is
based on microvascular disease risk, and
this has also been true for blood pressure
targets.ADA’s“StandardsofMedicalCare
in Diabetes—2010” does not state that
glycemic control reduces cardiovascular
riskbuturgesthatmorerandomizedcon-
trolled trials be carried out to assess the
hypothesis (25). Kendall stated, “Epide-
miologyoftenexaggeratesbut. . .itrarely
lies,” suggesting that ultimately it will be
shown that all the treatable factors associ-
ated with macrovascular disease in type 2
diabetes, LDL and HDL cholesterol, A1C,
blood pressure, and cigarette use (26),
will be found to be worth treating.
Examining the history of cardiovas-
cularrisktargets,theLDLtargetwasorig-
inally 160 mg/dl, the community target
for systolic blood pressure was 150
mmHg, and the A1C target was 8–9%.
Over time, the LDL target fell to 130
and then to 100, with current guide-
lines 70 mg/dl in the highest-risk indi-
viduals. For blood pressure, systolic
blood pressure goals for diabetic persons
decreased to 140 and then to 130
mmHg. Similarly, A1C targets decreased
to7–8inthe1990sandto6–7%overthe
past decade, although the latter goal re-
quires careful individualization.
A number of trials have addressed
blood pressure in diabetes: the Systolic
Hypertension in the Elderly Program
(SHEP), Hypertension Optimal Treat-
ment (HOT), Systolic Hypertension in
Europe(Syst-Eur),FosinoprilVersusAm-
lodipine Cardiovascular Events Random-
ized Trial (FACET), Appropriate Blood
Pressure Control in Diabetes (ABCD),
UKPDS, Heart Outcomes Prevention
Evaluation (HOPE), Antihypertensive
andLipid-LoweringTreatmenttoPrevent
Heart Attack Trial (ALLHAT), and
ADVANCE, with most showing improve-
ment in outcome, using a variety of treat-
ment approaches. In UKPDS, each 10
mmHgdecreaseinsystolicbloodpressure
wasassociatedwithreductionbothofmi-
crovascular events and of myocardial in-
farction by 15% (27). Kendall pointed
out that U-shaped curves with adverse
outcomeatlowaswellasathighlevelsare
shown in many blood pressure epidemi-
ologicanalyses,butwhetherthisindicates
adverse effect of treatment or coexisting
illness is not clear. It is not clear whether
the evidence supports a systolic blood
pressure goal 130 mmHg, and none of
the randomized controlled trials showed
this. The ACCORD substudy targeting
systolic blood pressure 120 mmHg was
reported subsequent to Kendall’s lecture,
showing some adverse effects, although
there was substantial reduction in stroke,
which might be important in certain pop-
ulations (28).
For lipids, LDL 100 mg/dl is the
primary goal, with levels 70 mg/dl an
option for those with overt CVD; much
lessisknownabouttriglycerideandHDL.
Statinshavebeenshownofbeneﬁt,witha
meta-analysis of 18,686 diabetic patients
showing a 31% reduction in vascular
mortality, 22% reduction in myocardial
infarction or coronary death, 21% reduc-
tion in stroke, and 25% reduction in cor-
onary revascularization for every 39
mg/dl reduction in LDL cholesterol (29).
There is, however, substantial residual
riskevenwithgoodLDLcontrol,whether
lipid-relatedorfromotherriskfactors.Fi-
brates (30), niacin (31), and other agents
have not been fully explored in diabetes,
but may be of beneﬁt. In the Fenoﬁbrate
Intervention and Event Lowering in Dia-
betes (FIELD) study, there was no signif-
icant beneﬁt of addition of fenoﬁbrate
(32). The ACCORD statin plus ﬁbrate
substudy was reported subsequent to
Kendall’s lecture and also failed to show
reduction in cardiovascular events (33),
although there is some evidence from the
study of improvement in retinopathy
(34).Whatisneeded,Kendallconcluded,
is comprehensive cardiovascular risk fac-
tor improvement, of the sort reported in
the Steno-2 study, in which modest indi-
vidual interventions on blood pressure,
lipids, glucose, aspirin use, and cigarette
smoking reduced risk by half (35), with
substantial long-term reduction in mor-
tality (36). We should maintain “thera-
peutic optimism” for glycemic treatment,
particularly early in the course of diabe-
tes, with diabetes prevention as the goal,
and lipid and blood pressure treatment is
important as well.
Lifestyle intervention
Gretchen Youssef (Washington, DC) dis-
cussed lifestyle interventions in a number
of diabetes and CVD trials, DCCT and
UKPDS, ACCORD, BARI 2D, VADT, and
Look AHEAD (Action for Health in Dia-
betes). Diabetes self-management educa-
tion (DSME) involves assessing the
knowledge skills and then developing a
plan for each individual patient in the
content areas of healthy eating, being ac-
tive, taking medications, monitoring,
problem-solving, healthy coping, and re-
ducing risks. Medical nutrition therapy
provides nutrition assessment, planning,
and support while reinforcing the DSME
content areas with individualized modiﬁ-
cation of food plan/physical activity/
medication for improved postmeal
glycemic control and hypoglycemia pre-
vention. It involves individualized modi-
ﬁcation of carbohydrate, protein, fat and
sodium intake, with guidance to achieve
lipid and blood pressure goals, and indi-
vidualized weight loss planning and
coaching.
TheADAstandardssuggestthatevery
person with diabetes should receive
DSME according to the national stan-
dards when diabetes is diagnosed and
thereafter. Medicare allows reimburse-
ment for 10 h of education (1 h individ-
ual, 9 h group) in the ﬁrst year and2ho f
either group or individual in subsequent
years of diabetes, with medical nutrition
therapy (MNT) reimbursed for3ha l -
lowed in the ﬁrst and2hi nsubsequent
years.MNTiseffective,Youssefsaid,with
evidence of beneﬁt of many types of nu-
trition intervention throughout the dis-
ease process, particularly at initial
diagnosis, although multiple encounters
arenecessary(37).TheAmericanDietetic
Association recommends that MNT pro-
vided by a registered dietitian be offered
to all individuals with diabetes, in a series
of three to four encounters each lasting
45–90 min, after which additional MNT
may be needed.
Youssef reviewed the use of MNT in
clinical trials. The DCCT was a model, in
which each person received a meal plan
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120% ideal body weight, with exercise
encouraged, the intensive group seen
monthly,andthestandardgroupseenev-
ery 6 months. The food pyramid, ex-
change system, carbohydrate counting,
and assessment of total available glucose
were taught to participants (38). In
UKPDS, MNT was individualized for all
participants,contributingtothe1.9%de-
crease in A1C over the initial 3-month
run-in phase. In ACCORD, individual
recommendations were made, with the
goal 10% or 5–9 kg weight loss, as well as
Na restriction (see protocol at www.
accordtial.og/public/protocol_2005–05–11.
pdf). In BARI 2D, there were nutritionist
visits reviewing nutrition, behavior
change, and physical activity at 3 months
and annually, with a goal loss of 10% of
weight for BMI 25 kg/m
2, with addi-
tional sessions for patients not meeting
A1C, blood pressure, or lipid goals or
with gain of 5% of original weight (see
protocol, adapted from the Diabetes
Prevention Program [DPP] approach,
at www.bari2d.org/researchers/manuals.
html). The VADT approach followed
ADA guidelines, with visits every 6 weeks
for the ﬁrst year and then quarterly. Fi-
nally, the Look AHEAD lifestyle interven-
tion trial was also adapted from DPP,
recordingfoodintake,restrictingcalories,
and developing portion control plans or
replacing two and then one meals daily
with liquid shake and using frozen en-
tre ´esfordinner.Thetrialusedtwotofour
visits monthly over the ﬁrst 4 years and
achieved 8.6 vs. 0.7% weight loss and 0.7
vs. 0.1% decrease from a baseline A1C of
7.3%, with increased ﬁtness and im-
provement in other measures (39).
Youssef concluded by stressing the
importance of culturally appropriate
meals, ﬁnancial considerations, content
appropriate for the health literacy level,
the use of individual and group MNT, the
need for multiple encounters and sup-
port, and the beneﬁt of regular physical
activity.Shenotedthatconsistencyacross
study sites and consistency of implemen-
tation are not always assured in clinical
trials, adding to the difﬁculty of translat-
ing studies into actual clinical use.
Clinical practice considerations
RichardBergenstal(Minneapolis,MN)re-
viewed the implications of the trials for
clinicalpractice.“Itreallyisaboutawhole
spectrum” of interventions, he said, in-
cluding self-management and lipid/blood
pressure/glycemic interventions. The
practice must be organized for success,
understanding factors predicting glyce-
mic control, agreeing on treatment goals,
and using appropriate tools. Factors pre-
dictingA1Cincludelifestyle,aboutwhich
Bergenstal commented that “it’s never too
late,” but a typical ﬁnding is that A1C is
lowest in patients on diet alone, interme-
diate in those receiving oral agents, and
highest in those treated with insulin (40),
suggesting that insulin is started too late
or that we do not really prescribe insulin
properly. He noted the importance of pa-
tientsandphysiciansagreeingondiabetes
management goals: if the patient is inter-
ested in their depression and the physi-
cian in A1C, blood pressure, and lipids, it
is difﬁcult to make headway; a recent
study showed that “30% of the time the
doctor’s top three weren’t even on the pa-
tient’s list” (41).
Bergenstal suggested that after one
gives the patient a plan (for example, tak-
ing aspirin; improving A1C, blood pres-
sure, and lipids; stopping cigarette use;
getting eye and foot exams; and checking
renal function), it is not advisable to ad-
dress each component at each visit, but
ratherthatseveralshouldbeworkedonat
each contact. Patients typically reported
hypoglycemia in ACCORD to be caused
by missed meals, which must be ad-
dressed by MNT. He cited Davidson’s in-
dictmentof“howourmedicalcaresystem
fails,” suggesting that disease manage-
ment reminders and laboratory reports
are not effective, with the only effective
interventions using proven algorithms
followed by specially trained staff to
change treatment (42). Which algorithm
is best? Bergenstal noted the ADA tier 1
and tier 2 recommendations, in which
metformin, sulfonylureas, and insulin are
given as ﬁrst choices (with which this
writer disagrees). He asked, what target?
Should the A1C be as low as possible?
Should one use eAG? Is it safe to drop the
A1Cquickly?Thereismicrovascularben-
eﬁt of glucose lowering in most studies,
and Bergenstal gave his belief that there is
cardiovascular “beneﬁt in the long run,”
but suggested that ACCORD aimed “too
low,” resulting in adverse effect in those
with intensive treatment who did not re-
spond, which he pointed out to be “the
groupyouhavetobackoffon.”Hefurther
noted that “relying on A1C alone is caus-
ing part of the problem,” as the practitio-
ner must target A1C and also self-
monitored glucose patterns. Perhaps
greater use of continuous glucose moni-
toring will allow better glycemic treat-
ment. He pointed out that not only A1C
and self-monitoring but also “minimizing
hypoglycemia and weight gain” are im-
portant,leadingtoconsiderationofuseof
-glucosidase inhibitors, amylin mimet-
ics, incretin-based treatments, and bile
acid sequestrants. Furthermore, he
stressedtheimportanceofthebloodpres-
sure, lipid, and A1C “triple goal” in opti-
mizing outcome. We need, he said,
aggressive early treatment “to undo 15
years of glucose exposure,” and we need
to make sure “not to push when we’re not
getting a response.”
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